Do all patients with metastatic colorectal cancer need chemotherapy until disease progression

Tara Beers Gibson, Axel F Grothey

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The question of continuous versus intermittent chemotherapy for patients with metastatic colorectal cancer has been an ongoing issue of debate for determining the optimum duration of treatment. The results from 2 major trials addressing this issue were recently presented at the 2006 Annual Meeting of the American Society of Clinical Oncology. The OPTIMOX2 trial evaluated the efficacy and safety of oxaliplatin reintroduction after a complete chemotherapy-free interval or maintenance therapy in patients with previously untreated disease. The GISCAD (Italian Group for the Study of Digestive Tract Cancer) study investigated the utility of intermittent versus continuous irinotecan-based chemotherapy. Both studies demonstrated that chemotherapy can be administered intermittently without affecting the overall efficacy of treatment.

Original languageEnglish (US)
Pages (from-to)196-201
Number of pages6
JournalClinical Colorectal Cancer
Volume6
Issue number3
StatePublished - 2006

Fingerprint

Disease Progression
Colorectal Neoplasms
Drug Therapy
oxaliplatin
irinotecan
Gastrointestinal Tract
Safety
Therapeutics
Neoplasms

Keywords

  • Chemotherapy-free interval
  • FOLFOX4
  • FOLFOX7
  • Reintroduction

ASJC Scopus subject areas

  • Oncology

Cite this

Do all patients with metastatic colorectal cancer need chemotherapy until disease progression. / Gibson, Tara Beers; Grothey, Axel F.

In: Clinical Colorectal Cancer, Vol. 6, No. 3, 2006, p. 196-201.

Research output: Contribution to journalArticle

Gibson, Tara Beers ; Grothey, Axel F. / Do all patients with metastatic colorectal cancer need chemotherapy until disease progression. In: Clinical Colorectal Cancer. 2006 ; Vol. 6, No. 3. pp. 196-201.
@article{9ac166eafdf342ff8188b51f1f50935c,
title = "Do all patients with metastatic colorectal cancer need chemotherapy until disease progression",
abstract = "The question of continuous versus intermittent chemotherapy for patients with metastatic colorectal cancer has been an ongoing issue of debate for determining the optimum duration of treatment. The results from 2 major trials addressing this issue were recently presented at the 2006 Annual Meeting of the American Society of Clinical Oncology. The OPTIMOX2 trial evaluated the efficacy and safety of oxaliplatin reintroduction after a complete chemotherapy-free interval or maintenance therapy in patients with previously untreated disease. The GISCAD (Italian Group for the Study of Digestive Tract Cancer) study investigated the utility of intermittent versus continuous irinotecan-based chemotherapy. Both studies demonstrated that chemotherapy can be administered intermittently without affecting the overall efficacy of treatment.",
keywords = "Chemotherapy-free interval, FOLFOX4, FOLFOX7, Reintroduction",
author = "Gibson, {Tara Beers} and Grothey, {Axel F}",
year = "2006",
language = "English (US)",
volume = "6",
pages = "196--201",
journal = "Clinical Colorectal Cancer",
issn = "1533-0028",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Do all patients with metastatic colorectal cancer need chemotherapy until disease progression

AU - Gibson, Tara Beers

AU - Grothey, Axel F

PY - 2006

Y1 - 2006

N2 - The question of continuous versus intermittent chemotherapy for patients with metastatic colorectal cancer has been an ongoing issue of debate for determining the optimum duration of treatment. The results from 2 major trials addressing this issue were recently presented at the 2006 Annual Meeting of the American Society of Clinical Oncology. The OPTIMOX2 trial evaluated the efficacy and safety of oxaliplatin reintroduction after a complete chemotherapy-free interval or maintenance therapy in patients with previously untreated disease. The GISCAD (Italian Group for the Study of Digestive Tract Cancer) study investigated the utility of intermittent versus continuous irinotecan-based chemotherapy. Both studies demonstrated that chemotherapy can be administered intermittently without affecting the overall efficacy of treatment.

AB - The question of continuous versus intermittent chemotherapy for patients with metastatic colorectal cancer has been an ongoing issue of debate for determining the optimum duration of treatment. The results from 2 major trials addressing this issue were recently presented at the 2006 Annual Meeting of the American Society of Clinical Oncology. The OPTIMOX2 trial evaluated the efficacy and safety of oxaliplatin reintroduction after a complete chemotherapy-free interval or maintenance therapy in patients with previously untreated disease. The GISCAD (Italian Group for the Study of Digestive Tract Cancer) study investigated the utility of intermittent versus continuous irinotecan-based chemotherapy. Both studies demonstrated that chemotherapy can be administered intermittently without affecting the overall efficacy of treatment.

KW - Chemotherapy-free interval

KW - FOLFOX4

KW - FOLFOX7

KW - Reintroduction

UR - http://www.scopus.com/inward/record.url?scp=33750190310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750190310&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 196

EP - 201

JO - Clinical Colorectal Cancer

JF - Clinical Colorectal Cancer

SN - 1533-0028

IS - 3

ER -